Table 1.

Indinavir concentration (nM) in plasma, peripheral blood mononuclear cells (PBMCs), and lymph node mononuclear cells (LNMCs) in HIV-1-infected humans on oral indinavir therapy^a

	Plasma	PBMC	LNMC	LNMC/PBMC ratiob
HIV-positive patients on oral indinavir therapy
Patient A	1004	1401	489	0.35
Patient B	NA	1531	432	0.28
Patient C	NA	432	101	0.23

^aPatients received oral indinavir 800 mg TID as part of combination therapy for at least 1 month prior to testing. PBMCs were isolated from blood and LNMCs were isolated from lymph node tissue for drug analysis as previously described [17]. Intracellular concentration (nM) was calculated assuming an average intracellular volume of 4×10⁻⁹ mL per cell [22]. Reported pharmacokinetic parameters of indinavir include a C_max of 11000 nM and C_trough of 211 nM

^bRatio of intracellular drug concentration in LNMCs over intracellular concentration in PBMCs

NA data not available